Effects of enalapril maleate on survival of dogs with naturally acquired heart failure

Journal of the American Veterinary Medical Association

Volumn 213, Issue 11, 1998, Pages 1573-1577

  Ettinger, S J ^a   Benitz, A M ^b,d   Ericsson, G F ^c   Cifelli, S ^c   Jernigan, A D ^b,e   Longhofer, S L ^b,f   Trimboli, W ^c   Hanson, P D ^c  

^a California Animal Hospital   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d Hoechst Roussel Vet   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^f HESKA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; ENALAPRIL MALEATE; FUROSEMIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOG; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HEART DILATATION; HEART FAILURE; MALE; MITRAL VALVE REGURGITATION; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; SURVIVAL RATE; TREATMENT FAILURE; UREMIA; VETERINARY MEDICINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0032404115     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.1998.213.11.1573     Document Type: Article

References (15)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.
2. Swedberg K, Kjekshus J, Snapinn S. Effect of enalapril on mortality in congestive heart failure, follow-up survival data from the CONSENSUS trial. Drugs 1990;39(Suppl 4):49-52.
3. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
5. SOLVD Investigators. Effects of enalapril on mortality and lhe development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
6. Keene BW, Rush JE. Therapy of heart failure. In: Ettinger SW, Feldman EC, eds. Textbook of veterinary internal medicine. 4th ed. Philadelphia: WB Saunders Co, 1995;867-892.
7. Fox PR, Sisson DD. Angiotensin-converting enzyme inhibitors. In: Bonagura JD, Kirk RW, eds. Current veterinary therapy XII. Philadelphia: WB Saunders Co, 1995;786-791.
8. Calvert CA. Update: canine dilated cardiomyopathy. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XI. Philadelphia: WB Saunders Co, 1992;773-779.
9. Buchanan JW. Causes and prevalence of cardiovascular disease. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XI. Philadelphia: WB Saunders Co, 1992;647-655.
10. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254.
11. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardio 1993;72:3C-11C.
12. Braunwald E. ACE inhibitors - a cornerstone of the treatment of heart failure. N Engl J Med 1991;325:351-353.
13. IMPROVE Study Group. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the invasive multicenter prospective veterinary evaluation of enalapril study. J Vet Intern Med 1995;9:234-242.
14. COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the cooperative veterinary enalapril study group. J Vet Intern Med 1995;9:243-252.
15. Knight D. Pathophysiology of heart failure and clinical evaluation of cardiac function. In: Ettinger SJ, Feldman EC, eds. Textbook of veterinary internal medicine. 4th ed. Philadelphia: WB Saunders Co, 1995;844-867.